XY Capital Ltd Takes Position in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

XY Capital Ltd bought a new stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 67,209 shares of the company’s stock, valued at approximately $1,061,000. Dr. Reddy’s Laboratories accounts for about 0.5% of XY Capital Ltd’s investment portfolio, making the stock its 19th biggest position.

A number of other large investors have also recently made changes to their positions in the stock. Farther Finance Advisors LLC grew its position in shares of Dr. Reddy’s Laboratories by 43.2% during the 3rd quarter. Farther Finance Advisors LLC now owns 454 shares of the company’s stock worth $36,000 after buying an additional 137 shares in the last quarter. Van ECK Associates Corp boosted its holdings in shares of Dr. Reddy’s Laboratories by 64.3% in the 3rd quarter. Van ECK Associates Corp now owns 823 shares of the company’s stock valued at $64,000 after buying an additional 322 shares in the last quarter. Lifestyle Asset Management Inc. grew its position in shares of Dr. Reddy’s Laboratories by 3.2% in the 3rd quarter. Lifestyle Asset Management Inc. now owns 13,689 shares of the company’s stock worth $1,088,000 after buying an additional 422 shares during the last quarter. GAMMA Investing LLC lifted its position in Dr. Reddy’s Laboratories by 83.2% during the third quarter. GAMMA Investing LLC now owns 1,447 shares of the company’s stock valued at $115,000 after acquiring an additional 657 shares during the last quarter. Finally, Natixis Advisors LLC increased its position in shares of Dr. Reddy’s Laboratories by 7.2% during the third quarter. Natixis Advisors LLC now owns 10,937 shares of the company’s stock worth $869,000 after purchasing an additional 735 shares in the last quarter. 3.85% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have commented on RDY. Nomura cut Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th. StockNews.com lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th. Finally, Barclays dropped their price target on Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 6th.

Dr. Reddy’s Laboratories Trading Down 0.4 %

Shares of RDY stock opened at $13.89 on Monday. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38. The stock has a 50 day simple moving average of $14.78 and a 200-day simple moving average of $15.37. The company has a market cap of $11.59 billion, a price-to-earnings ratio of 22.12 and a beta of 0.50. Dr. Reddy’s Laboratories Limited has a 1-year low of $13.36 and a 1-year high of $16.89.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%. On average, equities research analysts expect that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current fiscal year.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.